Cargando…
Prolyl oligopeptidase inhibition reduces alpha‐synuclein aggregation in a cellular model of multiple system atrophy
Multiple system atrophy (MSA) is a fatal neurodegenerative disease where the histopathological hallmark is glial cytoplasmic inclusions in oligodendrocytes, rich of aggregated alpha‐synuclein (aSyn). Therefore, therapies targeting aSyn aggregation and toxicity have been studied as a possible disease...
Autores principales: | Cui, Hengjing, Kilpeläinen, Tommi, Zouzoula, Lydia, Auno, Samuli, Trontti, Kalevi, Kurvonen, Sampo, Norrbacka, Susanna, Hovatta, Iiris, Jensen, Poul Henning, Myöhänen, Timo T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505845/ https://www.ncbi.nlm.nih.gov/pubmed/34486218 http://dx.doi.org/10.1111/jcmm.16910 |
Ejemplares similares
-
Nonpeptidic
Oxazole-Based Prolyl Oligopeptidase Ligands
with Disease-Modifying Effects on α-Synuclein Mouse Models
of Parkinson’s Disease
por: Kilpeläinen, Tommi P., et al.
Publicado: (2023) -
Removal of prolyl oligopeptidase reduces alpha-synuclein toxicity in cells and in vivo
por: Svarcbahs, Reinis, et al.
Publicado: (2018) -
2-Imidazole as a Substitute for the Electrophilic
Group Gives Highly Potent Prolyl Oligopeptidase Inhibitors
por: Pätsi, Henri T., et al.
Publicado: (2021) -
Prolyl oligopeptidase inhibition reduces PolyQ aggregation and improves cell viability in cellular model of Huntington’s disease
por: Norrbacka, Susanna, et al.
Publicado: (2019) -
Prolyl Oligopeptidase Regulates Dopamine Transporter Oligomerization and Phosphorylation in a PKC- and ERK-Independent Manner
por: Julku, Ulrika H., et al.
Publicado: (2021)